lusutrombopag 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
thrombopoietin agonists	5059	1110766-97-6

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

lusutrombopag
S-888711
S 888711
mulpleta

a thrombopoietin receptor agonist

Molecular weight: 591.54
Formula: C29H32Cl2N2O5S
CLOGP: 7.92
LIPINSKI: 2
HAC: 7
HDO: 2
TPSA: 97.75
ALOGS: -6.61
ROTB: 13

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Feb. 18, 2019	EMA	SHIONOGI B.V.
July 31, 2018	FDA	SHIONOGI INC
Sept. 28, 2015	PMDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B02BX07	BLOOD AND BLOOD FORMING ORGANS ANTIHEMORRHAGICS VITAMIN K AND OTHER HEMOSTATICS Other systemic hemostatics

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Thrombocytopenic disorder	indication	302215000	DOID:1588

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.45	acidic
pKa2	7.41	acidic
pKa3	0.94	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
3MG	MULPLETA	SHIONOGI INC	N210923	July 31, 2018	RX	TABLET	ORAL	7601746	Sept. 5, 2024	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE WHO ARE SCHEDULED TO UNDERGO A PROCEDURE

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
3MG	MULPLETA	SHIONOGI INC	N210923	July 31, 2018	RX	TABLET	ORAL	July 31, 2023	NEW CHEMICAL ENTITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Thrombopoietin receptor	Membrane receptor	P40238	TPOR_HUMAN	AGONIST	EC50	7.08		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE

External reference:

ID	Source
6LL5JFU42F	UNII
D10476	KEGG_DRUG
4037779	VANDF
C4309207	UMLSCUI
CHEBI:136051	CHEBI
CHEMBL2107831	ChEMBL_ID
49843517	PUBCHEM_CID
DB13125	DRUGBANK_ID
9410	INN_ID
C000611387	MESH_SUPPLEMENTAL_RECORD_UI
10032	IUPHAR_LIGAND_ID
2054984	RXNORM
286900	MMSL
34734	MMSL
d08854	MMSL
017667	NDDF
773263005	SNOMEDCT_US
773265003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Mulpleta	HUMAN PRESCRIPTION DRUG LABEL	1	59630-551	TABLET, FILM COATED	3 mg	ORAL	NDA	26 sections